Knowledge base

Three metabolic research compounds with three different targets. NNMT, ERR receptors and AMPK. Level of action, time scale and literature compared. RUO.

Thymosin alpha-1 is a defined 28-amino-acid peptide; thymalin is a peptide extract from thymus tissue. What that means for characterisation and research. RUO.

Sermorelin and tesamorelin share the same GHRH 1-29 backbone but differ sharply in stability and half-life. Structure, DPP-4 and research model compared. RUO.

IGF-1 LR3 and IGF-1 DES both bypass the IGF-binding proteins, but by opposite routes. Structure, half-life and research model compared. RUO.

PT-141 is the active metabolite of melanotan 2: one amide group fewer. What that does to the receptor profile, the pigment response and the regulatory status, from a research perspective.

AOD-9604 is HGH fragment 176-191 with an extra tyrosine. What that single amino acid changes about labelling, stability and the research dossier, and why the clinical paths diverged.

PTD-DBM, AHK-Cu, GHK-Cu and TB-500 each act on the hair follicle by their own route. An overview of the Wnt pathway, the dermal papilla and how substantial the evidence is per peptide.

CJC-1295 with DAC binds to albumin and keeps working for days; without DAC (mod GRF 1-29) the effect lasts half an hour. Half-life, pulsatility and dosing frequency compared from a research perspective.

Cagrilintide and eloralintide act through the amylin receptor, tirzepatide and retatrutide through the incretin receptors. Two tables setting the published outcomes and tolerability side by side.

Eloralintide (LY3841136) is a selective amylin receptor agonist from Eli Lilly. What the phase 2 trial showed, and how it compares to cagrilintide, petrelintide and amycretin.